Continue to Site

Purdue researchers tout nasal tuberculosis vaccine development strategy

August 20, 2021 By Sean Whooley

Purdue tuberculosis vaccine-mittalLO — Dr. Mittal conducts research on the potential tuberculosis vaccine. [Image from Suresh Mittal/Purdue University]

Researchers at Purdue University and Houston Methodist Research Institute are touting a novel strategy for developing a tuberculosis (TB) vaccine.

Bacillus Calmette-Guérin (BCG) is widely used as a vaccine against TB, but the researchers say it has a variable protection against neonatal and adult pulmonary TB, with protection ranging from 0% to 80% among infants. Despite routine vaccinations for children, mycobacterium tuberculosis (Mtb) continues to disseminate into brain and tuberculosis meningitis.

Get the full story at our sister site, Drug Discovery & Development.

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.